Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Zanti

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Briefings in Bioinformatics|May 19, 2021
Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19Marios Tomazou, Marilena M Bourdakou, George Minadakis, et al.
Journal of Medical Genetics|December 18, 2025
Evidence for pathogenicity of <i>BRCA2</i> c.8351G>A p.(Arg2784Gln) and the challenges in classification of pathogenic variants with reduced penetranceSetareh Moghadasi, Maria Zanti, Fonnet Bleeker, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Genetic and Cellular Architecture of Breast Cancer Risk in Multi-Ancestry Studies of 159,297 Cases and 212,102 ControlsJames L Li, Maria Zanti, Jacob Williams, et al.
American Journal of Human Genetics|October 31, 2025
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
Medrxiv : the Preprint Server for Health Sciences|June 26, 2025
Analysis of <i>BRCA1</i>, <i>BRCA2</i> and <i>PALB2</i> related Fanconi anemia identifies scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
Medrxiv : the Preprint Server for Health Sciences|September 16, 2024
Analysis of more than 400,000 women provides case-control evidence for <i>BRCA1</i> and <i>BRCA2</i> variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Nature Communications|May 24, 2025
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Breast Cancer Research : BCR|December 29, 2024
Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk predictionKristia Yiangou, Nasim Mavaddat, Joe Dennis, et al.
Medrxiv : the Preprint Server for Health Sciences|February 27, 2024
Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk predictionKristia Yiangou, Nasim Mavaddat, Joe Dennis, et al.
Human Mutation|May 10, 2024
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to <i>BRCA1</i> and <i>BRCA2</i>Maria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Briefings in Bioinformatics|May 19, 2021
Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19Marios Tomazou, Marilena M Bourdakou, George Minadakis, et al.
Journal of Medical Genetics|December 18, 2025
Evidence for pathogenicity of <i>BRCA2</i> c.8351G>A p.(Arg2784Gln) and the challenges in classification of pathogenic variants with reduced penetranceSetareh Moghadasi, Maria Zanti, Fonnet Bleeker, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Genetic and Cellular Architecture of Breast Cancer Risk in Multi-Ancestry Studies of 159,297 Cases and 212,102 ControlsJames L Li, Maria Zanti, Jacob Williams, et al.
American Journal of Human Genetics|October 31, 2025
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
Medrxiv : the Preprint Server for Health Sciences|June 26, 2025
Analysis of <i>BRCA1</i>, <i>BRCA2</i> and <i>PALB2</i> related Fanconi anemia identifies scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
Medrxiv : the Preprint Server for Health Sciences|September 16, 2024
Analysis of more than 400,000 women provides case-control evidence for <i>BRCA1</i> and <i>BRCA2</i> variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Nature Communications|May 24, 2025
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Breast Cancer Research : BCR|December 29, 2024
Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk predictionKristia Yiangou, Nasim Mavaddat, Joe Dennis, et al.
Medrxiv : the Preprint Server for Health Sciences|February 27, 2024
Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk predictionKristia Yiangou, Nasim Mavaddat, Joe Dennis, et al.
Human Mutation|May 10, 2024
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to <i>BRCA1</i> and <i>BRCA2</i>Maria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Pageof 2